Functional nanoplatforms for enhancement of chemotherapeutic index

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 212-221

  Yang, Jaemoon ^a,b   Lee, Eugene ^a   Ku, Minhee ^a   Huh, Yong Min ^a,b   Cheong, Jae Ho ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Anti cancer agents; Cancer; Combination chemotherapy; Nanoparticle; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRIMER; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HOLLOW SILICA NANOPARTICLE; IRINOTECAN; LIPOSOME; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; METHOTREXATE; NANOPARTICLE; NATURAL POLYMER; OXALIPLATIN; PACLITAXEL; POLYMERIC NANOPARTICLE; POLYMERSOME; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BIOCOMPATIBILITY; BIODEGRADABILITY; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CHEMOSENSITIZATION; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; GENE TARGETING; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOSARCOMA; MICELLE; MOLECULAR WEIGHT; MORTALITY; NANOTECHNOLOGY; OVARY CANCER; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; STOMACH CANCER; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; TOXICITY; TUMOR RECURRENCE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; RECURRENCE;

EID: 84876701193     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020005     Document Type: Review

References (142)

1. Reya, T.; Morrison, S.; Clarke, M., Weissman, I. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
2. Nguyen, L. V.; Vanner, R.; Dirks, P. Eaves, C. J. Cancer stem cells: An evolving concept. Nature Rev. Cancer, 2012, 12, 133-143.
3. Perry, M. C. The Chemotherapy Source Book, 3rd edition. Philadelphia: Lippincott Williams & Wilkins., 2001.
4. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
5. McNeil, S. E. Nanoparticle therapeutics: a personal perspective. Wiley Interdisciplinary Reviews: Nanomedicine and Nano-biotechnology, 2009, 1, 264-271.
6. Greco, F., Vicent, M. J. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev., 2009, DOI:10.1016/j.addr. 2009.05.006
7. James, N. D.; Coker, R. J.; Tomlinson, D.; Harris, J. R. W.; Gompels, M.; Pinching, A. J. Stewart, J. S. W. Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol., 1994, 6, 294-296.
8. Fujiwara, K. Clinical aspect of Doxil. Drug Delivery System, 2009, 24, 35-37.
9. Skubitz, K. M. Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in sarcoma. Cancer Investigation, 2003, 21, 167-176.
10. Skubitz, K. M. Phase II trial of pegylated-liposomal doxorubicin (Doxil™)in renal cell cancer. Investigational New Drugs, 2002, 20, 101-104.
11. Cho, K.; Wang, X.; Nie, S.; Chen, Z. Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
12. Sinha, R.; Kim, G. J.; Nie, S. Shin, D. M. Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Molecular Cancer Therapeutics, 2006, 5, 1909-1917.
13. Shapira, A.; Livney, Y. D.; Broxterman, H. J. Assaraf, Y. G. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resistance Updates, 2011, 14, 150-163.
14. Yaeger, K. A. Kurt, R. A. Construction and Evaluation of a Combined Cyclophosphamide/Nanoparticle Anticancer Vaccine.J. Cancer Therapy, 2011, 2, 384-393
15. Kim, J.-H.; Kim, Y.-S.; Park, K.; Lee, S.; Nam, H. Y.; Min, K. H.; Jo, H. G.; Park, J. H.; Choi, K.; Jeong, S. Y.; Park, R.-W.; Kim, I.-S.; Kim, K. Kwon, I. C. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release, 2008, 127, 41-49.
16. Cheng, L.; Jin, C.; Lv, W.; Ding, Q., Han, X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS ONE, 2011, 6.
17. Furgeson, D. Y.; Dreher, M. R. Chilkoti, A. Structural optimization of a smart doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. J. Control. Release 2006, 110, 362-369.
18. Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J.-S.; Huh, Y.-M.; Kim, K. Haam, S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials, 2010, 31, 4592-4599.
19. Yang, J.; Lee, C.-H.; Ko, H.-J.; Suh, J.-S.; Yoon, H.-G.; Lee, K.; Huh, Y.-M., Haam, S. Multifunctional Magneto-Polymeric Nanohybrids for Targeted Detection and Synergistic Therapeutic Effects on Breast Cancer. Angew. Chem.-Int. Edit., 2007, 46, 8836-8839.
20. Seo, D.-H.; Jeong, Y.-I.; Kim, D.-G.; Jang, M.-J.; Jang, M.-K. Nah, J.-W. Methotrexate-incorporated polymeric nanoparticles of methoxy poly(ethylene glycol)-grafted chitosan. Colloids and Surfaces B: Biointerfaces, 2009, 69, 157-163.
21. Nair K. L.; Jagadeeshan, S.; Nair, S. A., Kumar, G. V. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int. J. Nanomedicine, 2011, 6, 1685-1697.
22. Xiao, K.; Luo, J.; Fowler, W. L.; Li, Y.; Lee, J. S.; Xing, L.; Cheng, R. H.; Wang, L. Lam, K. S. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials, 2009, 30, 6006-6016.
23. Yadav, K. S., Sawant, K. K. Formulation Optimization of Etoposide Loaded PLGA Nanoparticles by Double Factorial Design and their Evaluation Current Drug Deliv., 2010, 7, 51-64
24. Cascone, M. G.; Pot, P. M.; Lazzeri, L. Zhu, Z. Release of dexamethasone from PLGA nanoparticles entrapped into dextran/ poly(vinyl alcohol) hydrogels. J. Materials Science: Materials in Medicine, 2002, 13, 265-269.
25. Gabizon, A.; Shmeeda, H.; Horowitz, A. T. Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Delivery Rev., 2004, 56, 1177-1192.
26. Gabizon, A., Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Nat. Acad. Sci. U.S.A., 1988, 85, 6949-6953.
27. MN, R. K. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci., 2000, 3, 234-258.
28. Almeida, A. J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Delivery Rev., 2007, 59, 478-490.
29. Kim, G. M.; Bae, Y. H. Jo, W. H. pH-induced Micelle Formation of Poly(histidine-co-phenylalanine)-block-Poly(ethylene glycol) in Aqueous Media. Macromol. Biosci., 2005, 5, 1118-1124.
30. Liu, S. Q.; Tong, Y. W. Yang, Y. Y. Thermally sensitive micelles self-assembled from poly(N-isopropylacrylamide-co-N,N- dimethylacrylamide)-b-poly(D,Llactide-co-glycolide) for controlled delivery of paclitaxel. Mol. BioSyst., 2005, 1, 158-165.
31. Bae, Y.; Diezi, T. A.; Zhao, A. Kwon, G. S. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 2007, 122, 324-330.
32. Lee, H.; Hu, M.; Reilly, R. M., Allen, C. Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol. Pharm., 2007, 4, 769-781.
33. Yoo, H. S.; Lee, K. H.; Oh, J. E., Park, T. G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Controlled Release, 2000, 68, 419-431.
34. Fonseca, C.; Simões, S., Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Controlled Release, 2002, 83, 273-286.
35. Cheng, F.-Y.; Wang, S. P.-H.; Su, C.-H.; Tsai, T.-L.; Wu, P.-C.; Shieh, D.-B.; Chen, J.-H.; Hsieh, P. C.-H. Yeh, C.-S. Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials, 2008, 29, 2104-2112.
36. Discher, B. M.; Won, Y.-Y.; Ege, D. S.; Lee, J. C.-M.; Bates, F. S.; Discher, D. E. Hammer, D. A. Polymersomes: Tough Vesicles Made from Diblock Copolymers. Science, 1999, 284, 1143-1146.
37. Christian, D. A.; Cai, S.; Bowen, D. M.; Kim, Y.; Pajerowski, J. D. Discher, D. E. Polymersome carriers: From self-assembly to siRNA and protein therapeutics. European J. Pharmaceutics and Biopharmaceutics, 2009, 71, 463-474.
38. Anraku, Y.; Kishimura, A.; Kobayashi, A.; Oba, M. Kataoka, K. Size-controlled long-circulating PICsome as a ruler to measure critical cut-off disposition size into normal and tumor tissues. Chemical Communications, 2011, 47, 6054-6056.
39. Kishimura, A.; Liamsuwan, S.; Matsuda, H.; Dong, W.-F.; Osada, K.; Yamasaki, Y., Kataoka, K. pH-dependent permeability change and reversible structural transition of PEGylated polyion complex vesicles (PICsomes) in aqueous media. Soft Matter, 2009, 5, 529-532.
40. Discher, D. E. Ahmed, F., Polymersomes. 2006; Vol. 8, pp 323-341.
41. Florence, A. T. Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Deliv. Rev., 2001, 50, S69-S89.
42. Bhattarai, N.; Gunn, J. Zhang, M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv. Drug Deliv. Rev., 2010, 62, 83-99.
43. Young, S.; Wong, M.; Tabata, Y. Mikos, A. G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Controlled Release, 2005, 109, 256-274.
44. Kashyap, N.; Kumar, N. Kumar, M. N. V. R. Hydrogels for pharmaceutical and biomedical applications. Critical Reviews in Therapeutic Drug Carrier Systems, 2005, 22, 107-149.
45. Ruel-Gariépy, E.; Shive, M.; Bichara, A.; Berrada, M.; Le Garrec, D.; Chenite, A., Leroux, J. C. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur. J. Pharmaceutics and Biopharmaceutics, 2004, 57, 53-63.
46. Mitra, S.; Gaur, U.; Ghosh, P. C. Maitra, A. N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Controlled Release, 2001, 74, 317-323.
47. Lu, J.; Liong, M.; Li, Z.; Zink, J. I. Tamanoi, F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small, 2010, 6, 1794-1805.
48. Slowing, I.; Trewyn, B. G. Lin, V. S. Y. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J.Am. Chem. Society, 2006, 128, 14792-14793.
49. Rim, H. P.; Min, K. H.; Lee, H. J.; Jeong, S. Y., Lee, S. C. pH-Tunable Calcium Phosphate Covered Mesoporous Silica Nanocontainers for Intracellular Controlled Release of Guest Drugs. Angewandte Chemie International Edition, 2011, 50, 8853-8857.
50. Chen, J. F.; Ding, H. M.; Wang, J. X. Shao, L. Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials, 2004, 25, 723-727.
51. Yang, J.; Lee, J.; Kang, J.; Lee, K.; Suh, J. S.; Yoon, H. G.; Huh, Y. M. Haam, S. Hollow silica nanocontainers as drug delivery vehicles. Langmuir, 2008, 24, 3417-3421.
52. Cao, S. W.; Zhu, Y. J.; Ma, M. Y.; Li, A., Zhang, L. Hierarchically nanostructured magnetic hollow spheres of Fe 3O4 and γ-Fe2O3: Preparation and potential application in drug delivery. J.Phys. Chem. C, 2008, 112, 1851-1856.
53. Shin, J.; Anisur, R. M.; Ko, M. K.; Im, G. H.; Lee, J. H. Lee, I. S. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angewandte Chemie - International Edition, 2009, 48, 321-324.
54. Liu, Z.; Tabakman, S.; Welsher, K., Dai, H. Carbon nanotubes in biology and medicine: In vitro and in vivo detection, imaging and drug delivery. Nano Res., 2009, 2, 85-120.
55. Zhang, X.; Meng, L.; Lu, Q.; Fei, Z. Dyson, P. J. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials, 2009, 30, 6041-6047.
56. Lasic, D. D. Needham, D. The Stealth liposome: A prototypical biomaterial. Chem. Rev., 1995, 95, 2601-2628.
57. Leamon, C. P.; Cooper, S. R. Hardee, G. E. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjugate Chemistry, 2003, 14, 738-747.
58. Liu, X. Y.; Ruan, L. M.; Mao, W. W.; Wang, J. Q.; Shen, Y. Q., Sui, M. H. Preparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects. Int. J. Med. Sci., 2010, 7, 197-208.
59. Félix, M. M.; Umakoshi, H.; Shimanouchi, T.; Yoshimoto, M., Kuboi, R. Evaluation of interaction between liposome membranes induced by stimuli responsive polymer and protein. J. Bioscience and Bioengineering, 2002, 93, 498-501.
60. Yudina, A.; De Smet, M.; Lepetit-Coiffé, M.; Langereis, S.; Van Ruijssevelt, L.; Smirnov, P.; Bouchaud, V.; Voisin, P.; Grüll, H., Moonen, C. T. W. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J. Controlled Release, 2011, 155, 442-448.
61. Ji, X.; Gao, Y.; Chen, L.; Zhang, Z.; Deng, Y. Li, Y. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance. Int. J. Pharmaceutics, 2012, 422, 390-397.
62. P., S. Lipidnanopellets als Tragersystem fur Arzneimittel zur perolen Anwendung. European Patent, 1990, EP 0167825.
63. Xu, Z.; Chen, L.; Gu, W.; Gao, Y.; Lin, L.; Zhang, Z.; Xi, Y. Li, Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials, 2009, 30, 226-232.
64. AEB, Y.; MK, A.; HA, M.; IM, E.-B.; MA, B. IA., A. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int. J. Med. Sci., 2010, 7, 398-408.
65. Dong, X.; Mattingly, C. A.; Tseng, M. T.; Cho, M. J.; Liu, Y.; Adams, V. R. Mumper, R. J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res., 2009, 69, 3918-3926.
66. Liu, P.; Wang, B. Li, W. Q. J. Multi-anticancer drugs encapsulated in the micelle: A novel chemotherapy to cancer. Medical Hypotheses, 2008, 71, 379-381.
67. Kim, D.; Lee, E. S.; Oh, K. T.; Gao, Z. G. Bae, Y. H. Doxorubicin-Loaded Polymeric Micelle Overcomes Multidrug Resistance of Cancer by Double-Targeting Folate Receptor and Early Endosomal pH. Small, 2008, 4, 2043-2050.
68. Dhar, S.; Gu, F. X.; Langer, R.; Farokhza, O. C. Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA - PEG nanoparticles. Proc. Nat. Acad.Sci. U.S.A., 2008, 105, 17356-17361.
69. Bermudez, H.; Brannan, A. K.; Hammer, D. A.; Bates, F. S. Discher, D. E. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules, 2002, 35, 8203-8208.
70. Ghoroghchian, P. P.; Frail, P. R.; Susumu, K.; Blessington, D.; Brannan, A. K.; Bates, F. S.; Chance, B.; Hammer, D. A. Therien, M. J. Near-infrared-emissive polymersomes: Self-assembled soft matter for in vivo optical imaging. Proc. Nat. Acad.Sci. U.S.A., 2005, 102, 2922-2927.
71. Li, S.; Byrne, B.; Welsh, J. Palmer, A. F. Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. Biotechnology Progress, 2007, 23, 278-285.
72. Sanson, C.; Schatz, C.; Le Meins, J. F.; Soum, A.; Thévenot, J.; Garanger, E., Lecommandoux, S. A simple method to achieve high doxorubicin loading in biodegradable polymersomes. J. Controlled Release, 2010, 147, 428-435.
73. Ahmed, F.; Pakunlu, R. I.; Brannan, A.; Bates, F.; Minko, T. Discher, D. E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J. Controlled Release, 2006, 116, 150-158.
74. Levine, D. H.; Ghoroghchian, P. P.; Freudenberg, J.; Zhang, G.; Therien, M. J.; Greene, M. I.; Hammer, D. A. Murali, R. Polymersomes: A new multi-functional tool for cancer diagnosis and therapy. Methods, 2008, 46, 25-32.
75. Kumar Upadhyay, K.; Le Meins, J. F.; Misra, A.; Voisin, P.; Bouchaud, V.; Ibarboure, E.; Schatz, C. Lecommandoux, S. Biomimetic doxorubicin loaded polymersomes from hyaluronan-block- poly(γ-benzyl glutamate) copolymers. Biomacromolecules, 2009, 10, 2802-2808.
76. Bhadra, D.; Bhadra, S.; Jain, S. Jain, N. K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. International Journal of Pharmaceutics, 2003, 257, 111-124.
77. Konishi, M.; Tabata, Y.; Kariya, M.; Suzuki, A.; Mandai, M.; Nanbu, K.; Takakura, K. Fujii, S. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J. Controlled Release, 2003, 92, 301-313.
78. Varghese, O. P.; Sun, W.; Hilborn, J., Ossipov, D. A. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: A hydrogel linked prodrug approach. J. the American Chemical Society, 2009, 131, 8781-8783.
79. Liu, Z.; Sun, X.; Nakayama-Ratchford, N. Dai, H. Supramolecular chemistry on water- Soluble carbon nanotubes for drug loading and delivery. ACS Nano, 2007, 1, 50-56.
80. Reya, T.; Morrison, S. J.; Clarke, M. F. Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
81. Pardal, R.; Clarke, M. F. Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nature Reviews Cancer, 2003, 3, 895-902.
82. Dalerba, P.; Cho, R. W. Clarke, M. F., Cancer stem cells: Models and concepts. 2007; Vol. 58, pp 267-284.
83. Heiden, M. G. V.; Cantley, L. C. Thompson, C. B. Understanding the warburg effect: The metabolic requirements of cell proliferation. Science, 2009, 324, 1029-1033.
84. Brigger, I. e.; Dubernet, C., Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
85. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y., Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Controlled Release, 2000, 65, 271-284.
86. Byrne, J. D.; Betancourt, T. Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1615-1626.
87. Yoo, H. S. Park, T. G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control. Release 2004, 100, 247-256.
88. Yang, J.; Lee, J.; Kang, J.; Oh, S. J.; Ko, H.-J.; Son, J.-H.; Lee, K.; Suh, J.-S.; Huh, Y.-M., Haam, S. Smart Drug-Loaded Polymer Gold Nanoshells for Systemic and Localized Therapy of Human Epithelial Cancer. Adv. Mater., 2009, 21, 4339-4342.
89. Acharya, S.; Dilnawaz, F. Sahoo, S. K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials, 2009, 30, 5737-5750.
90. Jiang, J.; Yang, S. J.; Wang, J. C.; Yang, L. J.; Xu, Z. Z.; Yang, T.; Liu, X. Y. Zhang, Q. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharmaceutics and Biopharmaceutics, 2010, 76, 170-178.
91. Medema, J. P. Vermeulen, L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature, 2011, 474, 318-326.
92. Lee, E. S.; Na, K. Bae, Y. H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103, 405-418.
93. Lim, E. K.; Huh, Y. M.; Yang, J.; Lee, K.; Suh, J. S. Haam, S. PH-triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv. Materials, 2011, 23, 2436-2442.
94. Minko, T.; Kopečková, P.; Pozharov, V., Kopeček, J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Controlled Release, 1998, 54, 223-233.
95. Malugin, A.; Kopečková, P. Kopeček, J. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J. Controlled Release, 2007, 124, 6-10.
96. Morrow, C. S., Cowan, K. H. Mechanisms and clinical significance of multidrug resistance. Oncology (Williston Park, N.Y.), 1988, 2, 55-63, 66.
97. Pallis, M.; Turzanski, J.; Higashi, Y. Russell, N. P-glycoprotein in acute myeloid leukaemia: Therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leukemia and Lymphoma, 2002, 43, 1221-1228.
98. Sakaeda, T.; Nakamura, T. Okumura, K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharma-codynamics of drugs. Pharmacogenomics, 2003, 4, 397-410.
99. Vasir, J. K. Labhasetwar, V. Targeted drug delivery in cancer therapy. Technol. in Cancer Res. and Treatment, 2005, 4, 363-374.
100. Polgar, O.; Robey, R. W. Bates, S. E. ABCG2: Structure, function and role in drug response. Expert Opin. Drug Metabolism and Toxicol., 2008, 4, 1-5.
101. D., K. L., X. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr. Drug Targets, 2010, 11, 699-707.
102. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S. Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treatment Reviews, 2008, 34, 592-602.
103. Dong, X. Mumper, R. J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine, 2010, 5, 597-615.
104. Zhang, H.; Jiang, H.; Wang, X. Chen, B. Reversion of multidrug resistance in tumor by biocompatible nanomaterials. Mini-Reviews in Medicinal Chemistry, 2010, 10, 737-745.
105. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E. Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391, 806-811.
106. Novina, C. D. Sharp, P. A. The RNAi revolution. Nature, 2004, 430, 161-164.
107. Woodle, M. C., Lu, P. Y. Nanoparticles deliver RNAi therapy. Materials Today, 2005, 8, 34-41.
108. Nakamura, K.; Abu Lila, A. S.; Matsunaga, M.; Doi, Y.; Ishida, T., Kiwada, H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol. Therapy, 2011, 19, 2040-2047.
109. George, J.; Banik, N. L. Ray, S. K. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG Cells. Neurochemical Res., 2009, 34, 66-78.
110. Wang, Y.; Gao, S.; Ye, W.-H.; Yoon, H. S., Yang, Y.-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater, 2006, 5, 791-796.
111. Cao, N.; Cheng, D.; Zou, S.; Ai, H.; Gao, J. Shuai, X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials, 2011, 32, 2222-2232.
112. Chen, A. M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T. He, H. Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells. Small, 2009, 5, 2673-2677.
113. Fuessel, S.; Herrmann, J.; Ning, S.; Kotzsch, M.; Kraemer, K.; Schmidt, U.; Hakenberg, O. W.; Wirth, M. P. Meye, A. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Letters, 2006, 232, 243-254.
114. Hussain, M.; Beale, G.; Hughes, M., Akhtar, S. Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. Int. J.Pharmaceutics, 2002, 234, 129-138.
115. Huang, H.-Y.; Kuo, W.-T.; Chou, M.-J. Huang, Y.-Y. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. Journal of Biomedical Materials Research Part A, 2011, 97A, 330-338.
116. Zhu, C.; Jung, S.; Luo, S.; Meng, F.; Zhu, X.; Park, T. G. Zhong, Z. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL- PDMAEMA triblock copolymers. Biomaterials, 2010, 31, 2408-2416.
117. Niu, J.; Li, X.-n.; Qian, H., Han, Z. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J. Cancer Res. Clin. Oncol., 2008, 134, 503-513.
118. Dickerson, E. B.; Blackburn, W. H.; Smith, M. H.; Kapa, L. B.; Lyon, L. A., McDonald, J. F. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer, 2010, 10.
119. Koga, K.; Hattori, Y.; Komori, M.; Narishima, R.; Yamasaki, M.; Hakoshima, M.; Fukui, T. Maitani, Y. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Science, 2010, 101, 941-947.
120. Chen, X. L.; Cao, L. Q.; She, M. R.; Wang, Q.; Huang, X. H., Fu, X. H. Gli-1 siRNA induced apoptosis in Huh7 cells. World J. Gastroenterology, 2008, 14, 582-589.
121. Cai, X.-M.; Xie, H.-L.; Liu, M.-Z. Zha, X.-L. Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin. BMC Biotechnology, 2008, 8, 74-80.
122. Suzuki, K.; Kokuryo, T.; Senga, T.; Yokoyama, Y.; Nagino, M. Hamaguchi, M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Science, 2010, 101, 1163-1169.
123. Ito, M.; Yamamoto, S.; Nimura, K.; Hiraoka, K.; Tamai, K. Kaneda, Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Medicine, 2005, 7, 1044-1052.
124. Dong, X.; Liu, A.; Zer, C.; Feng, J.; Zhen, Z.; Yang, M., Zhong, L. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer, 2009, 9.
125. Ma, X.; Zhang, J.; Liu, S.; Huang, Y.; Chen, B. Wang, D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemotherapy and Pharmacol., 2011, 1-10.
126. Pakunlu, R. I.; Wang, Y.; Tsao, W.; Pozharov, V.; Cook, T. J. Minko, T. Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense. Cancer Res., 2004, 64, 6214-6224.
127. Saad, M.; Garbuzenko, O. B. Minko, T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 2008, 3, 761-776.
128. Patutina, O. A.; Mironova, N. L.; Popova, N. A.; Kaledin, V. I.; Nikolin, V. P.; Vlassov, V. V. Zenkova, M. A. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer, 2010, 10.
129. Zhao, X.; Yang, L., Hu, J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J. Experimental and Clin. Cancer Res., 2011, 30.
130. Liang, Z.; Wu, H.; Xia, J.; Li, Y.; Zhang, Y.; Huang, K.; Wagar, N.; Yoon, Y.; Cho, H. T.; Scala, S. Shim, H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol., 2010, 79, 817-824.
131. Chen, Y.; Zuo, J.; Liu, Y.; Gao, H., Liu, W. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. Chinese J. Cancer, 2010, 29, 1006-1011.
132. Kim, H. J.; Eun, J. Y.; Jeon, Y. W.; Yun, J.; Kim, K. H.; Kim, S. H.; Kim, H. J.; Lee, S.-C.; Bae, S. B.; Kim, C. K.; Lee, N. S.; Lee, K. T.; Park, S.-K.; Won, J.-H.; Hong, D. S. Hee Sook Park, M. Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer. Cancer Res. Treat., 2011, 43, 154-159.
133. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T. Sasisekharan, R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 2005, 436, 568-572.
134. Yang, J.; Lee, C.-H.; Park, J.; Seo, S.; Lim, E.-K.; Song, Y. J.; Suh, J.-S.; Yoon, H.-G.; Huh, Y.-M., Haam, S. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J. Mater. Chem., 2007, 17, 2695-2699.
135. Kim, K. In Tumor homing nanoparticles for cancer imaging and therapy, 2009.
136. Kim, K.; Kim, J. H.; Park, H.; Kim, Y. S.; Park, K.; Nam, H.; Lee, S.; Park, J. H.; Park, R. W.; Kim, I. S.; Choi, K.; Kim, S. Y. Kwon, I. C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release, 2010, 146, 219-227.
137. Kim, J. I.; Lee, B. S.; Chun, C.; Cho, J. K.; Kim, S. Y. Song, S. C. Long-term theranostic hydrogel system for solid tumors. Biomaterials, 2011.
138. Yu, M. K.; Jeong, Y. Y.; Park, J.; Park, S.; Kim, J. W.; Min, J. J.; Kim, K. Jon, S. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angewandte Chemie - International Edition, 2008, 47, 5362-5365.
139. Liu, Y.; Miyoshi, H., Nakamura, M. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int.J. Cancer, 2007, 120, 2527-2537.
140. Min, K. H.; Park, K.; Kim, Y.-S.; Bae, S. M.; Lee, S.; Jo, H. G.; Park, R.-W.; Kim, I.-S.; Jeong, S. Y.; Kim, K., Kwon, I. C. Hydro-phobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 2008, 127, 208-218.
141. Kim, K.; Kim, J. H.; Park, H.; Kim, Y.-S.; Park, K.; Nam, H.; Lee, S.; Park, J. H.; Park, R.-W.; Kim, I.-S.; Choi, K.; Kim, S. Y.; Park, K. Kwon, I. C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release, 2010, 146, 219-227.
142. Yang, J.; Choi, J.; Bang, D.; Kim, E.; Lim, E.-K.; Park, H.; Suh, J.-S.; Lee, K.; Yoo, K.-H.; Kim, E.-K.; Huh, Y.-M. Haam, S. Convertible Organic Nanoparticles for Near-Infrared Photothermal Ablation of Cancer Cells. Angewandte Chemie International Edition, 2011, 50, 441-444.